DiagnaMed Holdings Corp. (DMED) AI Stock Analysis

• Market Cap: C$10.92M
• Dividend Yield: N/A
• Average Volume (3M): 717.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.58
• Revenue Growth: N/A
• EPS Growth: -67.11%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 109,158,970
• 10 Day Avg. Volume: 538,664
• 30 Day Avg. Volume: 717,725
• PEG Ratio: 0.03
• Price to Book (P/B): -3.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 33 Underperform
• Price Target: ―

DiagnaMed Holdings Corp. faces severe financial challenges with zero revenue and negative equity, significantly impacting its overall score. While recent corporate events offer some potential for growth in hydrogen technology and ALS treatment, the stock's negative valuation and bearish technical indicators underline the ongoing risks. Immediate corrective actions are crucial to improve financial health and investor confidence.

Positive Factors

FDA Orphan Drug Designation

This designation provides tax credits and market exclusivity, enhancing DiagnaMed's ability to accelerate development programs and potentially improving its market position in rare disease therapeutics.

Hydrogen Technology Commercialization

Progress in hydrogen technology can open new revenue streams and align with global low-carbon energy trends, strengthening DiagnaMed's market presence and operational capabilities.

Private Placement Funding

The funding supports R&D and commercialization efforts, potentially enhancing DiagnaMed's product offerings and market competitiveness in cleantech and life sciences sectors.

Negative Factors

Zero Revenue

The inability to generate revenue indicates significant challenges in market penetration and product monetization, threatening long-term financial sustainability and growth potential.

Negative Equity

Negative equity reflects financial distress and declining stability, limiting DiagnaMed's ability to invest in growth opportunities and potentially impacting its creditworthiness.

Negative Cash Flow

Inefficient cash management and lack of positive cash flow conversion from operations stress financial instability, hindering DiagnaMed's ability to fund operations and strategic initiatives.

DiagnaMed Holdings Corp. Business Overview & Revenue Model

Company Description

Diagnamed Holdings Corp. engages in developing a platform of software-based prescription digital therapeutic products for detecting brain age and tremors for neurological disorders. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

DiagnaMed Holdings Corp. generates revenue primarily through the sale of its diagnostic and monitoring solutions to healthcare providers, clinics, and hospitals. The company employs a revenue model that includes direct sales of its proprietary devices and software, as well as subscription-based services for data analytics and monitoring platforms. Key revenue streams also include licensing agreements for its technology and potential partnerships with other healthcare entities to co-develop and distribute innovative health solutions. Additionally, DiagnaMed may engage in strategic collaborations with research institutions and technology firms to enhance its product offerings and expand its market reach.

DiagnaMed Holdings Corp. Financial Statement Overview

Summary

DiagnaMed Holdings Corp. is struggling with zero revenue and substantial losses, leading to financial instability. The negative equity and cash flow performance highlight significant operational and strategic challenges. Immediate corrective actions are necessary to enhance financial health.

Income Statement

The company has consistently reported zero revenue across all periods, indicating challenges in generating sales. The net losses are significant, with no visible improvement in profitability. EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The equity has turned negative in the most recent TTM, indicating financial distress. The company has no debt, which is positive, but the negative stockholders' equity is a major concern. The equity ratio has deteriorated over time, showcasing declining financial stability.

Cash Flow

There is a negative trend in operating and free cash flows, demonstrating inefficient cash management. The company is facing challenges in converting operations into positive cash flow, with no growth in free cash flow. The cash flow situation further stresses financial instability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-24.71K	-16.05K
EBITDA	-1.16M	-501.00K	-100.00K	-1.13M	-1.95M
Net Income	-1.13M	-501.00K	-1.28M	-1.13M	-1.95M
Balance Sheet
Total Assets	288.11K	201.75K	662.27K	1.62M	2.39M
Cash, Cash Equivalents and Short-Term Investments	261.46K	162.15K	606.96K	1.57M	2.36M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	386.00K	466.91K	426.38K	369.51K	150.24K
Stockholders Equity	-97.89K	-265.17K	235.89K	1.25M	2.24M
Cash Flow
Free Cash Flow	-278.79K	-444.82K	-1.07M	-787.58K	-565.60K
Operating Cash Flow	-278.79K	-444.82K	-1.07M	-787.58K	-565.60K
Investing Cash Flow	0.00	0.00	0.00	0.00	34.07K
Financing Cash Flow	367.75K	0.00	104.25K	0.00	2.89M

DiagnaMed Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DMED, the sentiment is Positive. The current price of 0.11 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 82.30 is Negative, neither overbought nor oversold. The STOCH value of 80.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DMED.

DiagnaMed Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADK	50 Neutral	C$40.34M	-6.92	―	―	-48.53%	-9.66%
AIDR	48 Neutral	C$62.88M	-4.01	-207.53%	―	―	7.04%
CHS	45 Neutral	C$11.40M	-3.21	―	―	16.04%	-455.38%
UDOC	44 Neutral	C$11.66M	-2.77	―	―	―	48.94%
NARA	42 Neutral	C$7.16M	-1.79	―	―	―	81.01%
DMED	33 Underperform	C$10.92M	-8.66	―	―	―	-67.11%

DiagnaMed Holdings Corp. Corporate Events

DiagnaMed Expands Natural Hydrogen Portfolio with Strategic Acquisition in Nova Scotia

DiagnaMed Holdings Corp. has entered into an acquisition agreement to acquire the Colchester East Natural Hydrogen Project in Nova Scotia, which consists of 30 licenses totaling 2,104 claims. This strategic move places DiagnaMed in a prominent position within Canada’s burgeoning natural hydrogen corridor, aligning it with major industry players like Koloma and Rio Tinto. The acquisition enhances DiagnaMed’s existing land holdings and supports its strategy to advance next-generation hydrogen extraction technologies. The addition of Fabrice Consalvo to the Board of Directors further strengthens the company’s governance and technical focus as it expands its natural hydrogen portfolio.

DiagnaMed Expands Hydrogen Zone in Ontario’s Témiscamingue Graben

DiagnaMed Holdings Corp., in collaboration with Québec Innovative Materials Corp., has announced a significant expansion of the natural hydrogen system in Ontario’s Témiscamingue Graben by over 11 kilometers. The soil-gas survey results indicate high hydrogen concentrations, which support the company’s vision of establishing the Ontario-Quebec Hydrogen Corridor as a clean energy hub. This initiative is expected to enhance regional development and enable local communities to participate in Canada’s digital and energy economies.

DiagnaMed and QIMC Unveil Major Natural Hydrogen Discovery in Ontario

DiagnaMed Holdings Corp. and Québec Innovative Materials Corp. have announced a significant natural hydrogen discovery in Ontario’s Témiscamingue Graben, marking a pivotal development in their clean-tech initiatives. This discovery, characterized by high hydrogen concentrations, supports the establishment of the Ontario-Québec Natural Hydrogen Corridor, promising advancements in clean energy technology ecosystems. The companies are set to advance their exploration program, with plans for additional surveys and preliminary drilling, while maintaining partnerships with local communities and indigenous groups.